KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Net Cash Flow (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Net Cash Flow for 16 consecutive years, with $999000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 1507.04% year-over-year to $999000.0, compared with a TTM value of $2.1 million through Sep 2025, up 216.12%, and an annual FY2024 reading of $1.2 million, up 105.87% over the prior year.
  • Net Cash Flow was $999000.0 for Q3 2025 at TherapeuticsMD, up from $381000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $57.1 million in Q1 2021 and bottomed at -$140.8 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$9.0 million, with a median of -$229000.0 recorded in 2024.
  • The sharpest move saw Net Cash Flow skyrocketed 5515.14% in 2021, then tumbled 437.54% in 2022.
  • Year by year, Net Cash Flow stood at $47.8 million in 2021, then plummeted by 270.95% to -$81.8 million in 2022, then soared by 96.38% to -$3.0 million in 2023, then surged by 100.57% to $17000.0 in 2024, then skyrocketed by 5776.47% to $999000.0 in 2025.
  • Business Quant data shows Net Cash Flow for TXMD at $999000.0 in Q3 2025, $381000.0 in Q2 2025, and $699000.0 in Q1 2025.